Regeneration Biomedical, Inc. Press Releases - EIN Presswire

Published on December 18, 2025 - 14:34 GMT

Regeneration Biomedical Strengthens IP Portfolio with Direct-to-Brain Wnt-Activated Stem Cell Patent for Alzheimer's.

“RBI's Wnt-activated stem cell test product and preparation, designed to be injected directly into the ventricles of the brain, receives USPTO patent allowance” NEWPORT BEACH, CA, UNITED STATES, December 18, 2025 /⁨EINPresswire.com⁩/ -- Regeneration …

Distribution channels: Conferences & Trade Fairs, Culture, Society & Lifestyle ...

Published on December 1, 2025 - 23:00 GMT

RBI, Inc. to Present their Phase 1 First-in-Human, Direct-to-Brain Autologous Stem Cell Therapy Results at CTAD 2025

Addressing the need for alternative approaches to the treatment of Alzheimer's disease, RBI takes a different route - direct injection into the brain. SAN DIEGO, CA, UNITED STATES, December 1, 2025 /⁨EINPresswire.com⁩/ -- Regeneration Biomedical, Inc …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on December 1, 2025 - 17:00 GMT

Regeneration Biomedical, Inc. to Present First-in-Human Direct-to-Brain Autologous Stem Cell Therapy Data at CTAD 2025

RBI’s treatment injects a patient’s own Wnt-expressing stem cells directly into the brain’s ventricles—Results of their completed Phase 1 Trial are presented SAN DIEGO, CA, UNITED STATES, December 1, 2025 /⁨EINPresswire.com⁩/ -- Regeneration Biomedical, …

Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs ...

Published on September 23, 2025 - 16:00 GMT

RBI Advances World’s First Direct-to-Brain Autologous Stem Cell Therapy for Alzheimer’s Into Phase 2 Clinical Trial

Regeneration Biomedical’s Phase 2 trial of novel direct-to-brain autologous stem cell therapy for Alzheimer’s disease has cleared a 30-day review with the FDA. NEWPORT BEACH, CA, UNITED STATES, September 23, 2025 /⁨EINPresswire.com⁩/ -- Key Takeaways: • …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on August 25, 2025 - 16:00 GMT

Exclusive: Safe, Direct-to-Brain Autologous Stem Cell Therapy Shows Promise in Alzheimer’s

A Phase 1, "first-in-mankind" trial of stem cells injected directly into the brain, is safe with early signs of efficacy; FDA submission made for Phase 2 trial. NEWPORT BEACH, CA, UNITED STATES, August 25, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...